SynthesisBreast (Edinburgh, Scotland)2026
Beyond the first dose: Systematic review on external beam radiotherapy for locoregional breast cancer recurrence.
Synthesis in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal management of locoregional breast cancer recurrence after prior radiotherapy remains challenging. Reirradiation (ReRT) may allow repeat breast-conserving surgery as an alternative to mastectomy; however, prospective evidence is scarce, and existing data are largely retrospective, with the strongest support for brachytherapy. Despite this, external beam reirradiation (EBreRT) is widely used because of its availability. This systematic review evaluated the feasibility, oncologic outcomes, toxicity, and patient-reported outcomes of external-beam ReRT for locoregional breast cancer recurrence.
methodsFollowing the PRISMA guidelines (PROSPERO CRD420251003760), seven databases were searched until November 2025 to identify studies evaluating adjuvant external beam reirradiation for locoregional breast cancer recurrence. The outcomes of interest included disease control, survival, toxicity, and patient-reported outcomes, which were summarized descriptively.
resultsTwenty-four studies published between the mid-1980s and 2024, comprising 1252 patients, were included; most were retrospective, heterogeneous, single-institution cohorts with moderate quality. Reirradiation was predominantly delivered as partial-breast photon-based EBreRT using conventional fractionation.
conclusionsEvidence on EBreRT for locoregional breast cancer recurrence remains insufficient to define optimal dose regimens, treatment intervals, or standardized patient selection criteria, as the available studies are predominantly retrospective and heterogeneous. Nevertheless, the available data suggest that EBreRT may be a feasible therapeutic option, provided that careful case-by-case patient selection is applied.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.